AbbVie Inc. and InterMune Inc. could derail the European Medicines Agency's (EMA) carefully timetabled introduction of a new data transparency regime on Jan. 1, 2014, by seeking court injunctions preventing the disclosure of clinical trial data for their respective principal products, Humira (adalimumab) and Esbriet (perfidenone). Read More

LONDON – Study of a family affected by an inherited neurological disease has helped to reveal the identity of an enzyme that could point the way to new therapies for cancer and cardiovascular disease. Read More

LONDON – It was money galore for UK biotech on Monday as the government Biomedical Catalyst fund announced its second round of grants, with 51 companies bagging a total of £47.2 million (US$70.2 million). Read More

LONDON – Progenitor Labs Ltd. has raised £4 million (US$5.8 million) in seed financing from the GlaxoSmithKline plc venture fund SR One, enabling the company to further develop its platform technology for screening for small molecules that promote the differentiation of endogenous adult stem cells. Read More

NeuroVive Pharmaceutical AB extended its drug pipeline by picking up a series of polyketide-based preclinical cyclophilin inhibitors from Biotica Technology Ltd., a UK pioneer of polyketide engineering, which is currently in administration. Read More

LONDON – Cell Medica Ltd. has attracted Kurt Gunter, a leader of cell therapy in the U.S., to be its chief medical officer, in one of five senior appointments that will see the London-based company scaling up to a global operation. Read More

• Riboxx Pharmaceuticals GmbH, of Radebeul, Germany, began a research collaboration with China National Biotech Group Co. Ltd., of Beijing, evaluating Riboxxim with one of CNBG's antigen's for an infectious disease. Read More